Request for Information: FDA IT Infrastructure Services
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The U.S. Food and Drug Administration (FDA) is conducting market research through a Request for Information (RFI) for IT Infrastructure Services. This RFI aims to gather industry insights and capabilities to inform a potential future solicitation. Responses are due by July 3, 2026.
Purpose
This RFI is issued by the FDA's Office of Digital Transformation (ODT) to conduct market research under FAR Part 10. The primary goal is to obtain information from industry regarding their capabilities and approaches for providing comprehensive IT Infrastructure Services. This will help the FDA determine if qualified sources exist to satisfy future agency requirements. This is not a Request for Quote (RFQ) or a commitment to award a contract.
Scope of Information Requested
The FDA is seeking feedback on several key areas, including:
- A proposed three-tiered hybrid pricing model (Firm Fixed Price, Variable Firm Fixed Price, and Billable Hours) for IT infrastructure operations.
- Defining clear boundaries between Variable FFP and Billable Hours to prevent overlapping charges.
- Management of End-of-Life (EOL) programs within different pricing models.
- Best practices for pricing the transition-in period from an incumbent vendor, potentially using Time and Materials (T&M).
- The feasibility of organizations assuming and managing the FDA's existing colocation data center lease, including any commercial constraints.
Response Requirements
Interested parties should submit responses via email to Michelle Dacanay. Responses must include the RFI number and description in the subject line and shall not exceed three (3) pages. Submissions should also include:
- Company Name and Mailing Address
- Point of Contact (name, phone, email)
- Unique Entity Identifier (UEI)
- Socio-Economic Status
- GSA Contract Number (if applicable) Proprietary, classified, confidential, or sensitive information should not be included. No phone calls will be accepted.
Key Dates & Contacts
- Response Due: July 3, 2026, by 8:00 PM ET
- Published: June 20, 2026
- Primary Contact: Michelle Dacanay, michelle.dacanay@fda.hhs.gov
- Secondary Contact: Phillip Frame, phillip.frame@fda.hhs.gov
Important Notes
This RFI is for planning purposes only and does not constitute a solicitation. The FDA will not make a selection decision or award a contract based on responses, nor will it acknowledge receipt or notify respondents of the review outcome. The government assumes no financial responsibility for response costs and will not pay for any information received. While a contract for these services is anticipated in the future, a solicitation is not currently available.